192 related articles for article (PubMed ID: 27013180)
1. Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data.
Lang K; McGarry LJ; Huang H; Dorer D; Kaufman E; Knopf K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):275-285.e1. PubMed ID: 27013180
[TBL] [Abstract][Full Text] [Related]
2. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
[TBL] [Abstract][Full Text] [Related]
3. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia.
Kenzik KM; Bhatia R; Williams GR; Bhatia S
Cancer; 2019 Aug; 125(15):2570-2578. PubMed ID: 30973642
[TBL] [Abstract][Full Text] [Related]
4. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis.
Brunner AM; Campigotto F; Sadrzadeh H; Drapkin BJ; Chen YB; Neuberg DS; Fathi AT
Cancer; 2013 Jul; 119(14):2620-9. PubMed ID: 23625575
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease.
Leong D; Aghel N; Hillis C; Siegal D; Karampatos S; Rangarajan S; Pond G; Seow H
Heart; 2021 Apr; 107(8):667-673. PubMed ID: 33419879
[TBL] [Abstract][Full Text] [Related]
6. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America.
Karalexi MA; Baka M; Ryzhov A; Zborovskaya A; Dimitrova N; Zivkovic S; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Demetriou A; Agius D; Florea M; Coza D; Polychronopoulou S; Stiakaki E; Moschovi M; Hatzipantelis E; Kourti M; Graphakos S; Pombo-de-Oliveira MS; Adami HO; Petridou ET
Eur J Cancer; 2016 Nov; 67():183-190. PubMed ID: 27677054
[TBL] [Abstract][Full Text] [Related]
7. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
Winn AN; Keating NL; Dusetzina SB
J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
[TBL] [Abstract][Full Text] [Related]
8. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis.
Chai-Adisaksopha C; Lam W; Hillis C
Leuk Lymphoma; 2016; 57(6):1300-10. PubMed ID: 26373533
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysis.
Menzin J; Lang K; Earle CC; Glendenning A
Drugs Aging; 2004; 21(11):737-46. PubMed ID: 15323579
[TBL] [Abstract][Full Text] [Related]
10. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
12. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto KJ; Fujita H; Fujioka I; Kimura Y; Aisa Y; Iwanaga E; Asou N; Kizaki M; Hatta Y; Komatsu N; Kawaguchi T
Med Oncol; 2018 May; 35(7):99. PubMed ID: 29846829
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013.
Beinortas T; Tavorienė I; Žvirblis T; Gerbutavičius R; Jurgutis M; Griškevičius L
BMC Cancer; 2016 Mar; 16():198. PubMed ID: 26956037
[TBL] [Abstract][Full Text] [Related]
14. Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor.
Uemura M; Imataki O; Kawachi Y; Kawakami K; Hoshijima Y; Matsuoka A; Kadowaki N
Int J Hematol; 2016 Nov; 104(5):621-627. PubMed ID: 27492732
[TBL] [Abstract][Full Text] [Related]
15. Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007.
Lin PJ; Winn AN; Parsons SK; Neumann PJ; Weiss ES; Cohen JT
Med Care; 2016 Apr; 54(4):380-5. PubMed ID: 26759984
[TBL] [Abstract][Full Text] [Related]
16. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
Shen C; Zhao B; Liu L; Shih YT
Cancer; 2018 Jan; 124(2):364-373. PubMed ID: 28976559
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results (SEER) analysis.
Wang Q; Jiang C; Zhang Y; Zhang Y; Yue B; Zheng-Lin B; Zhao Y; Mauro MJ
Leuk Lymphoma; 2020 May; 61(5):1147-1157. PubMed ID: 31985308
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.
Yin XF; Wang JH; Li X; Yu MX; Ma ZX; Jin J
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):577-581. PubMed ID: 27397576
[TBL] [Abstract][Full Text] [Related]
19. Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO.
Haque R; Shi J; Chung J; Xu X; Avila C; Campbell C; Ahmed SA; Chen L; Schottinger JE
J Am Pharm Assoc (2003); 2017; 57(3):303-310.e2. PubMed ID: 28259737
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.
Chiwata M; Itonaga H; Sato S; Hashimoto M; Fujioka M; Kasai S; Sakamoto H; Toriyama E; Nakashima J; Kamijo R; Kitanosono H; Kobayashi Y; Horai M; Taguchi M; Matsuo M; Makiyama J; Takasaki Y; Matsuo E; Horio K; Ando K; Sawayama Y; Taguchi J; Kawaguchi Y; Tsushima H; Imanishi D; Imaizumi Y; Yoshida S; Jo T; Nonaka H; Moriuchi Y; Nagai K; Yokota KI; Hata T; Miyazaki Y
Intern Med; 2021 Jul; 60(14):2207-2216. PubMed ID: 33612681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
